{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-25-000014","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.459027+00:00","generated_at":"2026-05-24T05:36:33.939212+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027","bullets":["Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.","Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.","Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.","Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.","Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-25-000014","json":"https://secwatch.observer/filing/0001372514-25-000014.json","markdown":"https://secwatch.observer/filing/0001372514-25-000014.md","text":"https://secwatch.observer/filing/0001372514-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/0001372514-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/kprx-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:36:33.939212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}